Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinisches Magazin
Erschienen in:

15.10.2018 | Pathologie

Gastrointestinale Stromatumoren

Bedeutung der molekularen Diagnostik für Prognose und Therapie

verfasst von: Priv.-Doz. Dr. Silke Cameron

Erschienen in: Wiener klinisches Magazin | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Vor 20 Jahren beschrieben Hirota et al. die Expression einer Rezeptortyrosinkinase des Protoonkogens KIT durch einen besonderen Typ mesenchymaler Tumoren des Gastrointestinaltrakts: den gastrointestinalen Stromatumor (GIST). Seither ist die molekulare Diagnostik auch im Hinblick auf therapeutische Möglichkeiten fortgeschritten.

Fragestellung

Dieser Artikel zeichnet die Bedeutung der unterschiedlichen Tyrosinkinase(TK)-Rezeptor-Mutationen sowie die nachgeschalteten Signalwege bis in den Nukleus und ihre Relevanz für die Pathogenese und Therapie der GIST nach.

Material und Methode

Die gängige internationale Literatur wurde strukturiert zur Beantwortung bisher unklarer Fragen zusammengestellt.

Ergebnisse

Während KIT in unterschiedlichen Zellen exprimiert wird (Cajal-Zellen, hämatopoietischen Stammzellen, Melanozyten, Mastzellen und Keimzellen), entstehen GIST aus Cajal-Zellen (oder deren Vorläufern). Somit muß ein definierter zellulärer Kontext für die Entwicklung von GIST bestehen. Mikro-GIST zeigen bereits die Treibermutation im Tyrosinkinaserezeptor, entwickeln sich jedoch erst zu manifesten GIST bei hoher endogener Expression des Transkriptionsfaktors ETV1. Wie KIT- und PDGFRA-Mutationen schließen sich KRAS- und BRAF-Mutationen gegenseitig aus. KRAS- und BRAF-Mutationen können als nachgeschaltete Mutationen vorkommen. Wildtyp(WT)-GIST mit ihren Unterformen der Succinatdehydrogenase(SDH)-Defizienz sind jedoch gesondert zu betrachten. Ob sekundäre Mutationen unter therapeutischem Selektionsdruck neu entstehen oder – bereits vorhanden – selektiert werden, ist bisher unklar. Sekundäre Mutationen scheinen jedoch erst ab einem bestimmten Expressionsniveau Relevanz zu besitzen. Die Therapie fortgeschrittener GIST ist aufgrund der komplexen genomischen Evolution und der Entwicklung von Resistenzen erschwert.

Schlussfolgerungen

Trotz Ihrer Seltenheit bleiben GIST auch für komplexe Therapiesituationen Modelltumoren.
Vorheriger Artikel Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts
Nächster Artikel Digitale Pathologie
Literatur
1.
Posner I, Engel M, Gazit A et al (1994) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol Pharmacol 45:673–683PubMed
2.
Ravegnini G, Sammarini G, Nannini M et al (2017) Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy 13:452–463CrossRefPubMedPubMedCentral
3.
Cameron S (2018) Gastrointestinaler Stromatumor (GIST). Thieme, Stuttgart, S 119–133
4.
Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c‑kit in human gastrointestinal stromal tumors. Science 279:577–580CrossRefPubMed
5.
Heinrich MC, Rubin BP, Longley BJ et al (2002) Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 33:484–495CrossRefPubMed
6.
Heinrich MC, Corless CL, Demetri GD et al (2003) Kinase mutations and Imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21:4342–4349CrossRefPubMed
7.
Heinrich MC, Corless CL, Duensing A et al (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708–710CrossRefPubMed
8.
Sakurai S, Hasegawa T, Sakuma Y et al (2004) Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 35:1223–1230CrossRefPubMed
9.
Martin-Broto J, Gutierrez A, Garcia-del-Muro X et al (2010) Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 21:1552–1557CrossRefPubMed
10.
Joensuu H, Wardelmann E, Sihto H et al (2017) Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant Imatinib: an exploratory analysis of a randomized clinical trial. Jama Oncol 3:602–609CrossRefPubMedPubMedCentral
11.
Altimari A, deBiase D, deMaglio G et al (2013) 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 6:1057–1064PubMedPubMedCentral
12.
13.
Wardelmann E, Merkelbach-Bruse S, Pauls K et al (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with Imatinib mesylate. Clin Cancer Res 12:1743–1749CrossRefPubMed
14.
Wozniak A, Rutkowski P, Schoffski P et al (2014) Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. Clin Cancer Res 20:6105–6116CrossRefPubMed
15.
Gajiwala KS, Wu JC, Christensen J et al (2009) KIT kinase mutants show unique mechanisms of drug resistance to Imatinib and Sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106:1542–1547CrossRefPubMedPubMedCentral
16.
17.
DeMatteo RP, Ballman KV, Antonescu CR et al (2009) Adjuvant Imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 373:1097–1104CrossRefPubMedPubMedCentral
18.
DeMatteo RP, Ballman KV, Antonescu CR et al (2013) Long-term results of adjuvant Imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 258:422–429CrossRefPubMedPubMedCentral
19.
Joensuu H, Eriksson M, Sundby HK et al (2012) One vs three years of adjuvant Imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307:1265–1272CrossRefPubMed
20.
21.
Heinrich MC, Owzar K, Corless CL et al (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of Imatinib mesylate for treatment of advanced gastrointestinal stromal tumor. J Clin Oncol 26:5360–5367 (CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group)CrossRefPubMedPubMedCentral
22.
Kunstlinger H, Huss S, Merkelbach-Bruse S et al (2013) Gastrointestinal stromal tumors with KIT exon 9 mutations: Update on genotype-phenotype correlation and validation of a high-resolution melting assay for mutational testing. Am J Surg Pathol 37:1648–1659CrossRefPubMed
23.
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of Sunitinib in patients with advanced gastrointestinal stromal tumour after failure of Imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed
24.
Heinrich MC, Maki RG, Corless CL et al (2008) Primary and secondary kinase genotypes correlate with the biological and clinical activity of Sunitinib in Imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352–5359CrossRefPubMedPubMedCentral
25.
Agaimy A, Bauer S, Beham A et al (2015) Gastrointestinal Stromal Tumours (GIST) – development in pathology, surgery and medical therapy. Z Gastroenterol 53:235–243CrossRefPubMed
26.
Heinrich MC, Marino-Enriquez A, Presnell A et al (2012) Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors. Mol Cancer Ther 11:1770–1780CrossRefPubMedPubMedCentral
27.
28.
Rini BI (2007) Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions. Clin Cancer Res 13:1098–1106CrossRefPubMed
29.
Demetri GD, Reichardt P, Kang YK et al (2013) Efficacy and safety of Regorafenib for advanced gastrointestinal stromal tumours after failure of Imatinib and Sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295–302CrossRefPubMed
30.
Garner AP, Gozgit JM, Anjum R et al (2014) Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Clin Cancer Res 20:5745–5755CrossRefPubMedPubMedCentral
31.
Bauer S, Joensuu H (2015) Emerging agents for the treatment of advanced, Imatinib-resistant gastrointestinal Stromal tumors: current status and future directions. Drugs 75:1323–1334CrossRefPubMedPubMedCentral
32.
Blay JY, Domont J, Cropet C et al (2015) LBA45A randomized multicentre phase II study of Pazopanib plus best supportive care (BSC) vs. BSC alone in metastatic gastrointestinal stromal tumors (GIST) resistant to Imatinib and Sunitinib. Ann Oncol 25(suppl 4):v41–v1. https://​doi.​org/​10.​1093/​annonc/​mdu438.​57 CrossRef
33.
Montemurro M, Schoffski P, Reichardt P et al (2009) Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both Imatinib and Sunitinib. Eur J Cancer 45:2293–2297CrossRefPubMed
34.
Mir O, Cropet C, Toulmonde M et al (2016) Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to Imatinib and Sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. Lancet Oncol 17:632–641CrossRefPubMed
35.
36.
Adenis A, Blay JY, Bui-Nguyen B et al (2014) Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of Imatinib: a randomized controlled open-label trial. Ann Oncol 25:1762–1769CrossRefPubMedPubMedCentral
37.
Miranda C, Nucifora M, Molinari F et al (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769–1776CrossRefPubMed
38.
Agaimy A, Terracciano LM, Dirnhofer S et al (2009) V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J Clin Pathol 62:613–616CrossRefPubMed
39.
Agaram NP, Wong GC, Guo T et al (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47:853–859CrossRefPubMedPubMedCentral
40.
Huss S, Pasternack H, Ihle MA et al (2017) Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events. Hum Pathol 62:206–214CrossRefPubMed
41.
Falchook GS, Trent JC, Heinrich MC et al (2013) BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor Dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget 4:310–315PubMedPubMedCentral
42.
43.
Wilhelm SM, Dumas J, Adnane L et al (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129:245–255CrossRefPubMed
44.
Andersson J, Sihto H, Meis-Kindblom JM et al (2005) NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am J Surg Pathol 29:1170–1176CrossRefPubMed
45.
Miettinen M, Lasota J (2014) Succinate dehydrogenase deficient gastrointestinal stromal tumors (GISTs) – A review. Int J Biochem Cell Biol 53:514–519CrossRefPubMed
46.
Soni S, Padwad YS (2017) HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol 56:503–515CrossRefPubMed
47.
48.
Belinsky MG, Rink L, Flieder DB et al (2013) Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 52:214–224CrossRefPubMed
49.
Lasota J, Wang Z, Kim SY et al (2013) Expression of the receptor for type i insulin-like growth factor (IGF1R) in gastrointestinal stromal tumors: an immunohistochemical study of 1078 cases with diagnostic and therapeutic implications. Am J Surg Pathol 37:114–119CrossRefPubMedPubMedCentral
50.
Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-STAT. Science 296:1653–1655CrossRefPubMed
51.
52.
Judson I, Scurr M, Gardner K et al (2014) Phase II study of Cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma. Clin Cancer Res 20:3603–3612CrossRefPubMed
53.
Joensuu H, Blay JY, Comandone A et al (2017) Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to Imatinib. Br J Cancer 117:1278–1285CrossRefPubMedPubMedCentral
54.
Zeng S, Seifert AM, Zhang JQ et al (2017) Wnt/beta-catenin signaling contributes to tumor malignancy and is targetable in gastrointestinal Stromal tumor. Mol Cancer Ther 16:1954–1966CrossRefPubMedPubMedCentral
55.
56.
Bertucci F, Finetti P, deNonneville A et al (2018) „Wnt/beta-Catenin in GIST“-Letter. Mol Cancer Ther 17:327–328CrossRefPubMed
57.
Chi P, Chen Y, Zhang L et al (2010) ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 467:849–853CrossRefPubMedPubMedCentral
58.
Zeng S, Seifert AM, Zhang JQ et al (2017) ETV4 collaborates with Wnt/beta-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor. Oncotarget 8:114195–114209PubMedPubMedCentral
59.
Pinto F, Campanella NC, Abrahao-Machado LF et al (2016) The embryonic Brachyury transcription factor is a novel biomarker of GIST aggressiveness and poor survival. Gastric Cancer 19:651–659CrossRefPubMed
60.
Kurrey NK, Jalgaonkar SP, Joglekar AV et al (2009) Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 27:2059–2068CrossRefPubMed
61.
Hamilton DH, David JM, Dominguez C et al (2017) Development of cancer vaccines targeting Brachyury, a transcription factor associated with tumor epithelial-Mesenchymal transition. Cells Tissues Organs (Print) 203:128–138CrossRef
62.
Cameron S, Gieselmann M, Blaschke M, al Ret (2014) Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). Int J Clin Exp Pathol 7:3563–3579PubMedPubMedCentral
63.
Rusakiewicz S, Semeraro M, Sarabi M et al (2013) Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 73:3499–3510CrossRefPubMed
64.
Wang H, Cheng F, Cuenca A et al (2005) Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T‑cell tolerance. Blood 105:1135–1143CrossRefPubMed
65.
Reilley MJ, Bailey A, Subbiah V et al (2017) Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer 5:35CrossRefPubMedPubMedCentral
66.
D’Angelo SP, Shoushtari AN, Keohan ML et al (2017) Combined KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas: a phase Ib study of Dasatinib plus Ipilimumab. Clin Cancer Res 23:2972–2980CrossRefPubMed
67.
Polier G, Neumann J, Thuaud F et al (2012) The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem Biol 19:1093–1104CrossRefPubMed
68.
Bauer S, Yu LK, Demetri GD et al (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66:9153–9161CrossRefPubMed
69.
Wagner AJ, Chugh R, Rosen LS et al (2013) A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res 19:6020–6029CrossRefPubMedPubMedCentral
70.
71.
Dickson MA, Okuno SH, Keohan ML et al (2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 24:252–257CrossRefPubMed
72.
Cameron S, Beham A, Schildhaus HU (2017) Current standard and future perspectives in the treatment of gastrointestinal Stromal tumors. Digestion 95:262–268CrossRefPubMed
73.
Bauer S, Hilger RA, Muhlenberg T et al (2014) Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors. Br J Cancer 110:1155–1162CrossRefPubMedPubMedCentral
74.
Mol CD, Dougan DR, Schneider TR et al (2004) Structural basis for the autoinhibition and STI-571 inhibition of c‑Kit tyrosine kinase. J Biol Chem 279:31655–31663CrossRefPubMed
75.
76.
Wang Y, Marino-Enriquez A, Bennett RR et al (2014) Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet 46:601–606CrossRefPubMedPubMedCentral
77.
Metadaten
Titel
Gastrointestinale Stromatumoren
Bedeutung der molekularen Diagnostik für Prognose und Therapie
verfasst von
Priv.-Doz. Dr. Silke Cameron
Publikationsdatum
15.10.2018
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 6/2018
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-018-0257-7

Weitere Artikel der Ausgabe 6/2018

Digitale Pathologie

  • Pathologie

Von der „biologischen Person“ zur Resonanz

  • Perspektiven

Medikamentöse Therapie neuroendokriner Neoplasien des Gastrointestinaltrakts

Probiotika bei Lebererkrankungen

  • Open Access
  • Gastroenterologie & Hepatologie

Spitzenmathematik in der Präzisionsmedizin

  • aktuell

Unangenehme Wahrheiten und Aufrichtigkeit

  • Editorial